Bicycle Therapeutics plc Fair Value Adjustment of Warrants
Bicycle Therapeutics plc (BCYC) reported Fair Value Adjustment of Warrants of $0 for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-03-01
- Bicycle Therapeutics plc fair value adjustment of warrants for the quarter ending 2020-09-30 was $0.00.
- Bicycle Therapeutics plc fair value adjustment of warrants for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Bicycle Therapeutics plc fair value adjustment of warrants for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Bicycle Therapeutics plc fair value adjustment of warrants for the quarter ending 2019-12-31 was $0.00.
- Bicycle Therapeutics plc fair value adjustment of warrants for fiscal 2019 was $5.38M, a 709.17% increase from fiscal 2018.
- Bicycle Therapeutics plc fair value adjustment of warrants for fiscal 2018 was $665.00K, a 458.82% increase from fiscal 2017.
- Bicycle Therapeutics plc fair value adjustment of warrants for fiscal 2017 was $119.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $2.20M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $2.20M derived: sum of 3 quarters · filed 2022-03-01 | $5.38M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $2.20M derived: sum of 2 quarters · filed 2020-11-05 | $5.38M 10-Q · filed 2020-11-05 | $4.59M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $2.20M 10-Q · filed 2020-08-05 | $5.38M 10-Q · filed 2020-08-05 | $4.59M derived: sum of 3 quarters · filed 2021-03-11 | $5.95M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $3.20M 10-Q · filed 2020-05-07 | $2.39M derived: sum of 2 quarters · filed 2021-03-11 | $3.75M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | -$807.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $554.00K derived: sum of 2 quarters · filed 2021-03-11 | $665.00K 10-K · filed 2021-03-11 | |
| 2018-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.47M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $111.00K 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $119.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |